India · Delayed Price · Currency is INR Bal Pharma Statistics
Total Valuation
Bal Pharma has a market cap or net worth of INR 1.32 billion. The enterprise value is 2.74 billion.
| Market Cap | 1.32B |
| Enterprise Value | 2.74B |
Important Dates
The last earnings date was Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | Sep 18, 2025 |
Share Statistics
| Current Share Class | 15.92M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.85% |
| Shares Change (QoQ) | -2.58% |
| Owned by Insiders (%) | 52.16% |
| Owned by Institutions (%) | n/a |
| Float | 5.47M |
Valuation Ratios
The trailing PE ratio is 18.44.
| PE Ratio | 18.44 |
| Forward PE | n/a |
| PS Ratio | 0.45 |
| PB Ratio | 1.70 |
| P/TBV Ratio | 2.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 38.22 |
| EV / Sales | 0.93 |
| EV / EBITDA | 9.17 |
| EV / EBIT | 14.18 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 1.97 |
| Debt / EBITDA | 5.10 |
| Debt / FCF | n/a |
| Interest Coverage | 1.16 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 5.50% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 2.99M |
| Profits Per Employee | 72,584 |
| Employee Count | 986 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -24.57M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.55% in the last 52 weeks. The beta is 0.18, so Bal Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -27.55% |
| 50-Day Moving Average | 85.60 |
| 200-Day Moving Average | 96.52 |
| Relative Strength Index (RSI) | 45.66 |
| Average Volume (20 Days) | 20,288 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bal Pharma had revenue of INR 2.95 billion and earned 71.57 million in profits. Earnings per share was 4.58.
| Revenue | 2.95B |
| Gross Profit | 1.42B |
| Operating Income | 192.91M |
| Pretax Income | 47.28M |
| Net Income | 71.57M |
| EBITDA | 298.40M |
| EBIT | 192.91M |
| Earnings Per Share (EPS) | 4.58 |
Balance Sheet
The company has 105.19 million in cash and 1.52 billion in debt, giving a net cash position of -1.42 billion.
| Cash & Cash Equivalents | 105.19M |
| Total Debt | 1.52B |
| Net Cash | -1.42B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 774.04M |
| Book Value Per Share | 39.09 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 48.28%, with operating and profit margins of 6.55% and 2.43%.
| Gross Margin | 48.28% |
| Operating Margin | 6.55% |
| Pretax Margin | 1.61% |
| Profit Margin | 2.43% |
| EBITDA Margin | 10.13% |
| EBIT Margin | 6.55% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 1.46%.
| Dividend Per Share | 1.20 |
| Dividend Yield | 1.46% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.85% |
| Shareholder Yield | 0.61% |
| Earnings Yield | 5.42% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |